Day Zero Diagnostics has appointed Dekel Gelbman as senior VP of business development and strategy, Robin Patel as a member of its scientific advisory board, and Sally Hojvat as a regulatory strategy advisor.
Gelbman joins the company from FDNA, where he was the founding CEO. Before that, he was a corporate and transactional attorney in Israel and the US.
Patel is the director of the infectious diseases research laboratory and co-director of the clinical bacteriology laboratory at the Mayo Clinic.
Hojvat is a senior consultant at Partners in Diagnostics. Prior to that, she was the director of the division of microbiology devices at the Center for Devices and Radiological Health at the US Food and Drug Administration.